Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence

Area of Science:

• Oncology
• Immunotherapy
• Cancer Treatment

Background:

• Recent FDA approvals in 2021-2022 highlight immune checkpoint inhibitors in the neoadjuvant setting for early-stage triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
• Emerging studies demonstrate both benefits and challenges of neoadjuvant immunotherapy prior to surgery across gastrointestinal, head and neck, and cutaneous cancers.
• The landscape of cancer treatment is shifting towards incorporating neoadjuvant immune strategies for early-stage diseases.

Purpose of the Study:

• To review the current evidence supporting the use of immune checkpoint inhibitors in the neoadjuvant setting.
• To discuss ongoing clinical trials investigating neoadjuvant immune treatments for early-stage cancers.
• To outline key clinical considerations for multidisciplinary cancer care teams regarding neoadjuvant immunotherapy versus upfront surgery.

Main Methods:

• Literature review of recent FDA approvals and published studies on neoadjuvant immunotherapy.
• Summary of ongoing Phase II and Phase III clinical trials in various cancer types.
• Analysis of clinical decision-making factors for neoadjuvant treatment versus immediate surgical intervention.

Main Results:

• Immune checkpoint inhibitors have gained traction in neoadjuvant treatment for TNBC and NSCLC.
• Evidence suggests efficacy and identifies challenges in applying neoadjuvant immunotherapy to diverse cancer types.
• Numerous trials are underway, indicating a growing role for this treatment modality.

Conclusions:

• Neoadjuvant immunotherapy represents a significant evolution in cancer care, offering new paradigms for early-stage disease.
• Anticipated approvals will expand indications for immune checkpoint inhibitors in neoadjuvant settings.
• Careful consideration of evidence, ongoing research, and multidisciplinary input is crucial for optimal patient management.